Smith and Nephew recently announced its Q3 trading update. Revenue was in line with expectations, coming in at $1,169m, up 3% on an underlying basis. Growth was largely driven by sports medicine joint repair, other surgical businesses and advanced wound devices. On the other hand, arthroscopic enabling technologies and advanced wound bioactives weighed on growth. The big (positive) surprises, though, were the knee segment and the US region. Our recommendation remains unchanged in spite of mar
13 Nov 2018
A progressive quarter but mixed guidance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A progressive quarter but mixed guidance
Smith & Nephew plc (SN:LON) | 957 -93.7 (-1.0%) | Mkt Cap: 8,364m
- Published:
13 Nov 2018 -
Author:
Kamla Singh -
Pages:
4
Smith and Nephew recently announced its Q3 trading update. Revenue was in line with expectations, coming in at $1,169m, up 3% on an underlying basis. Growth was largely driven by sports medicine joint repair, other surgical businesses and advanced wound devices. On the other hand, arthroscopic enabling technologies and advanced wound bioactives weighed on growth. The big (positive) surprises, though, were the knee segment and the US region. Our recommendation remains unchanged in spite of mar